Vancomycin nephrotoxicity: Myths and facts

Netherlands Journal of Medicine

Volumn 69, Issue 9, 2011, Pages 379-383

  Gupta, A ^a   Biyani, M ^a   Khaira, A ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Moolchand Hospital   (India)

Author keywords

Dose; Nephrotoxicity; Trough levels; Vancomycin

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CAFFEIC ACID PHENETHYL ESTER; CURCUMIN; ERYTHROPOIETIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; BULLOUS SKIN DISEASE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; FEVER; HUMAN; INCIDENCE; LACRIMATION; NECROTIZING ARTERITIS; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHLEBITIS; RED MAN SYNDROME; REVIEW; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS;

ACUTE KIDNEY INJURY; ANIMALS; HUMANS; RISK FACTORS; VANCOMYCIN;

EID: 80054681544     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-9.
2. Vandecasteele SJ, Boelaert JR, De Vriese AS. Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol. 2009;4:1388-400.
3. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42 Suppl 1:S5-12.
4. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925-42.
5. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507-14.
6. Nakamura T, Takano M, Yasuhara M, Inui K. In-vivo clearance study of vancomycin in rats. J Pharm Pharmacol. 1996;48:1197-200.
7. Dieterich C, Puey A, Lin S, et al. Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci. 2009;107:258-69.
8. Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother. 2001;13:461-72.
9. Nishino Y, Takemura S, Minamiyama Y, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res. 2003;37:373-9.
10. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology. 2005;215:227-33.
11. Hong S, Valderrama E, Mattana J, et al. Vancomycin-induced acute granulomatous interstitial nephritis: therapeutic options. Am J Med Sci. 2007;334:296-300.
12. Ahmida MH. Protective role of curcumin in nephrotoxic oxidative damage induced by vancomycin in rats. Exp Toxicol Pathol. 2010 Sep 8. [Epub ahead of print].
13. Ocak S, Gorur S, Hakverdi S, Celik S, Erdogan S. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol. 2007;100:328-33.
14. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol. 2007;34:1181-5.
15. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986;11:257-82.
16. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9:9-14.
17. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-44.
18. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29:1107-15.
19. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330-6.
20. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy. 1995;15:85-91.
21. Haque NZ, Kiyan PO, Reyers K, et al. Nephrotoxicity in Intensive Care Unit patients with Hospital-Acquired Pneumonia: the IMPACT-HAP Project. In: 47th Annual Meeting of Infectious Diseases Society of America. Arlington, VA: IDSA; 2009. Abstract 388.
22. Prabaker K, Tran T, Pratummas T, Goetz M, Graber C. Association of vancomycin trough levels with nephrotoxicity. In: 47th Annual Meeting of Infectious Diseases Society of America. Arlington, VA: IDSA; 2009. Abstract 192.
23. Nguyen M, Wong J, Lee C, et al. Nephrotoxicity associated with high dose vs. standard dose vancomycin therapy. In: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2007. Abstract K-1096.
24. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123:1143-9.
25. Mora A, Dzintars K, Lat A, Frei CR, Echevarria K. Incidence of vancomycin nephrotoxicity in the absence of concomitant nephrotoxins or confounders. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: ASM Press; 2009. Abstract A1-1294a.
26. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-6.
27. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009;34:570-4.
28. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Müller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion. Anesthesiology. 2009;111:356-65.
29. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29:351-7.
30. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42 Suppl 1:S35-9.
31. Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer. 1998;83:2597-607.
32. Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp. 1988;3:376-86.
33. Rocha JL, Kondo W, Baptista MI, Da Cunha CA, Martins LT. Uncommon vancomycin-induced side effects. Braz J Infect Dis. 2002;6:196-200.